Article
Medicine, General & Internal
Mu-Hung Tsai, Yung-Jen Cheng, Tzu-Hui Pao, Wei-Ting Hsueh, Helen H. W. Chen, Yuan-Hua Wu
Summary: This study compared the effectiveness of definitive chemoradiotherapy and upfront surgical treatment for advanced-stage oropharyngeal squamous cell carcinoma. The findings suggest that definitive chemoradiotherapy is comparable to upfront surgical treatment when adjusted for baseline factors associated with prognosis. Therefore, definitive chemoradiotherapy may be considered to avoid toxic effects associated with surgical treatment and chemoradiotherapy.
Article
Multidisciplinary Sciences
Tomohiko Ishikawa, Takenori Ogawa, Masahiro Shiihara, Hajime Usubuchi, Yuko Omori, Katsuya Hirose, Taito Itoh, Takuya Yoshida, Ayako Nakanome, Akira Okoshi, Kenjiro Higashi, Ryo Ishii, Masahiro Rokugo, Shun Wakamori, Yasunobu Okamura, Kengo Kinoshita, Yukio Katori, Toru Furukawa
Summary: This study established a translational model for testing the impact of molecular-targeted therapies on salivary gland cancers (SGCs) by combining patient-derived organoids and genomic analyses. The results showed that organoids retained most histopathological and genetic profiles of the original tumors and were valuable for testing genotype-oriented molecular-targeted therapy.
Article
Biology
Julie A. Hong, Bhadrasian Vikram, Jeffrey Buchsbaum, Jacek Capala, Alicia Livinski, Beverly Teicher, Pataje Prasanna, Mansoor M. Ahmed, Ceferino Obcemea, C. Norman Coleman, Michael Graham Espey
Summary: This study aims to evaluate the approaches used by cancer researchers to advance the combination of molecularly targeted agents and radiation treatment into early-phase clinical trials, highlighting the challenges faced in the translation of precision medicine and radiation oncology.
RADIATION RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Fabiola Sciscione, Simon Guillaume, Abil E. Aliev, Declan T. Cook, Hugo Bronstein, Helen C. Hailes, Paul C. Beard, Tammy L. Kalber, Olumide Ogunlade, Alethea B. Tabor
Summary: Semiconducting polymer nanoparticles (SPN) have potential as exogenous contrast agents for photoacoustic imaging (PAI), but require active targeting strategies and effective characterization techniques. This study developed EGFR-targeted SPN using peptide conjugation and a new NMR method. Preliminary experiments indicated ineffective delivery or destabilization of the formulation.
BIOORGANIC & MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Sabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, Claudia Kamfenkel, Oliver Politz, Christine Ellingsen, Jochen Hilbig, Mark U. Juul, Jesper Fonslet, Carsten H. Nielsen, Christoph A. Schatz, Roger M. Bjerke, Alan S. Cuthbertson, Dominik Mumberg, Urs B. Hagemann
Summary: Targeted alpha therapies (TAT) are an innovative class of therapies for cancer treatment that induce DNA double-strand breaks. Difficult to-treat cancers upregulating chemoresistance proteins and overexpressing membrane proteins are promising targets for TATs.
MOLECULAR CANCER THERAPEUTICS
(2023)
Review
Chemistry, Medicinal
Adileh Ayati, Setareh Moghimi, Mahsa Toolabi, Alireza Foroumadi
Summary: Despite advancements in cancer treatment, EGFR inhibitors have shown significant improvement in targeted therapy. However, the emergence of epigenetic mutation and resistance issues have limited their effectiveness, leading to the need for further research in this field. Recent studies have focused on genetic alterations in the EGFR tyrosine kinase domain, resulting in the development of more selective and effective inhibitors.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Bin Zhang, Zhikun Liu, Shengjin Xia, Qingqing Liu, Shaohua Gou
Summary: Multi-target, especially dual-target, drug design is a popular research field in cancer treatment. This study developed quinazoline derivatives as dual EGFR/CAIX inhibitors, with compound 8v showing potent anticancer activity against mutant-type lung cancer cells, especially under hypoxic conditions. Mechanism studies revealed that 8v exhibited strong inhibitory effects on both EGFR(T790M) and CAIX enzymes, making it a promising candidate for further research in cancer therapy.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Medicine, Research & Experimental
Francesca Citron, Ilenia Segatto, Lorena Musco, Ilenia Pellarin, Gian Luca Rampioni Vinciguerra, Giovanni Franchin, Giuseppe Fanetti, Francesco Micciche, Vittorio Giacomarra, Valentina Lupato, Andrea Favero, Isabella Concina, Sanjana Srinivasan, Michele Avanzo, Isabella Castiglioni, Luigi Barzan, Sandro Sulfaro, Gianluigi Petrone, Andrea Viale, Giulio F. Draetta, Andrea Vecchione, Barbara Belletti, Gustavo Baldassarre
Summary: EGFR activation upregulates miR-9 expression, sustaining aggressiveness and resistance to RT+CTX in HNSCC. miR-9 may serve as a valuable biomarker for selecting HNSCC patients who may benefit from RT+CTX therapy.
EMBO MOLECULAR MEDICINE
(2021)
Article
Chemistry, Medicinal
Aleksei E. Machulkin, Anastasia A. Uspenskaya, Nikolay Y. Zyk, Ekaterina A. Nimenko, Anton P. Ber, Stanislav A. Petrov, Radik R. Shafikov, Dmitry A. Skvortsov, Galina B. Smirnova, Yulia A. Borisova, Vadim S. Pokrovsky, Vasilii S. Kolmogorov, Alexander N. Vaneev, Yan A. Ivanenkov, Alexander D. Khudyakov, Sergei Kovalev, Alexander S. Erofeev, Petr Gorelkin, Elena K. Beloglazkina, Nikolay Zyk, Elena S. Khazanova, Alexander G. Majouga
Summary: The study focused on developing docetaxel conjugates for prostate cancer treatment, showing promising cytotoxicity and increased solubility compared to the drug itself. In vivo evaluation demonstrated strong inhibitory effects on tumor growth and lower toxicity compared to free docetaxel. The PSMA-targeted docetaxel conjugate is considered a good candidate for further preclinical trials due to its high antitumor activity, reduced side effects, and improved solubility.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Review
Biotechnology & Applied Microbiology
Colette Bilynsky, Nadine Millot, Anne-Laure Papa
Summary: Nanotechnologies have shown significant potential as radiosensitizers for enhancing the efficacy of radiation therapy in cancer treatment. This review systematically examines the use of nanoparticles (NPs) in preclinical and clinical studies, highlighting their design and effects. Human trials are discussed with a focus on their design and detailed clinical outcomes.
BIOENGINEERING & TRANSLATIONAL MEDICINE
(2022)
Review
Chemistry, Medicinal
Ranju Bansal, Anjleena Malhotra
Summary: Cancer is a serious health issue with available chemotherapeutic drugs being highly toxic and lacking selectivity. Advances in science have illuminated molecular pathways responsible for cancer, leading to the development of targeted anticancer agents, such as quinazoline derivatives. These agents act by inhibiting various protein kinases and other molecular targets, offering new opportunities for more effective cancer treatment.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Chemistry, Inorganic & Nuclear
Alexander Kastner, Theresa Mendrina, Florian Bachmann, Walter Berger, Bernhard K. Keppler, Petra Heffeter, Christian R. Kowol
Summary: In this study, oxaliplatin(iv)-based complexes were developed as platinum(iv) prodrugs to release aspirin, which has shown antitumor activity against colon cancer. The newly synthesized complex demonstrated increased reduction stability compared to a cisplatin analog and exhibited desired prodrug properties in cell culture. A derivative with albumin-binding properties showed improved pharmacokinetics and tumor accumulation, leading to enhanced antitumor activity and overall survival in tumor-bearing mice.
INORGANIC CHEMISTRY FRONTIERS
(2023)
Review
Oncology
Mercedes Herrera-Juarez, Cristina Serrano-Gomez, Helena Bote-de-Cabo, Luis Paz-Ares
Summary: Precision oncology aims to design the best cancer treatment based on tumor biology. In NSCLC, patients with actionable genomic aberrations can benefit from targeted therapy, such as EGFR mutations and ALK rearrangements. Effective inhibitors have been developed for various druggable targets, leading to a paradigm shift in NSCLC treatment.
Article
Oncology
Daiki Hara, Wensi Tao, Tulasigeri M. Totiger, Ali Pourmand, Nesrin Dogan, John Chetley Ford, Junwei Shi, Alan Pollack
Summary: This study developed PSMA-targeted gold nanoparticles to enhance prostate cancer therapy and established an X-ray fluorescence imaging system to monitor GNP delivery. Results showed enhanced tumor uptake and peak accumulation at approximately 24 hours after administration of PSMA-targeted GNPs. The XRFproj/XFCT imaging system proved to be accurate for quantifying GNPs within tumors noninvasively.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Pauliina M. Kitti, Maria Faltinova, Juha Kauppi, Jari Rasanen, Tiina Saarto, Tiina Seppala, Anu M. Anttonen
Summary: This study aimed to investigate the factors associated with the choice of treatment modality in locally advanced oesophageal cancer. The study found that the overall clinical status of the patients and the stage of the cancer can guide the choice of treatment modalities, but there is evidence of overtreatment. Additionally, smoking status is also associated with survival.
RADIATION ONCOLOGY
(2023)
Article
Respiratory System
Torsten Gerriet Blum, Rebecca L. Morgan, Valerie Durieux, Joanna Chorostowska-Wynimko, David R. Baldwin, Jeanette Boyd, Corinne Faivre-Finn, Francoise Galateau-Salle, Fernando Gamarra, Bogdan Grigoriu, Georgia Hardavella, Michael Hauptmann, Erik Jakobsen, Dragana Jovanovic, Paul Knaut, Gilbert Massard, John McPhelim, Anne-Pascale Meert, Robert Milroy, Riccardo Muhr, Luciano Mutti, Marianne Paesmans, Pippa Powell, Paul Martin Putora, Janette Rawlinson, Anna L. Rich, David Rigau, Dirk de Ruysscher, Jean-Paul Sculier, Arnaud Schepereel, Dragan Subotic, Paul Van Schil, Thomy Tonia, Clare Williams, Thierry Berghmans
Summary: This guideline provides good quality recommendations in lung cancer care, based on systematic reviews and evidence syntheses. The recommendations cover various quality improvement measures, such as avoiding delays in diagnosis and treatment, integrating multidisciplinary teams, adhering to guidelines, and using specific tools for decision-making. The recommendations should be periodically updated as new evidence becomes available.
EUROPEAN RESPIRATORY JOURNAL
(2023)
Article
Oncology
Alan McWilliam, Azadeh Abravan, Kathryn Banfil, Corinne Faivre-Finn, Marcel van Herk
Summary: The dose to the base of the heart is associated with overall survival, explaining the worse survival in the high-dose arm of lung cancer treatment. By avoiding the heart subregion dose, future dose escalation trials may be feasible.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Marina C. Garassino, Corinne Faivre-Finn
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Oncology
Saskia A. Cooke, Dirk de Ruysscher, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Corinne Faivre-Finn, Edith M. T. Dieleman, Rolf Lewensohn, Judi N. A. van Diessen, Karolina Sikorska, Ferry Lalezari, Wouter Vogel, Wouter van Elmpt, Eugene M. F. Damen, Jan -Jakob Sonke, Jose S. A. Belderbos
Summary: This study aimed to evaluate the ability of radiation dose escalation to improve local control in patients with locally advanced non-small-cell lung cancer. The results showed that both whole primary tumour dose escalation and PET-defined subvolume dose escalation can improve local control. However, both strategies also led to unexpected high rates of toxicity. Therefore, it is recommended to improve dose escalation strategies by considering dose differentiation, better patient selection, and improved protection of central structures.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Medicine, General & Internal
Fiona Blackhall, Nicolas Girard, Alain Livartowski, Laura McDonald, Montserrat Roset, Nuria Lara, Ariadna Juarez Garcia
Summary: This retrospective study analyzed the characteristics, treatment patterns, and clinical outcomes of patients with small-cell lung cancer (SCLC). The results showed that the prognosis of SCLC is still unsatisfactory, especially for patients with extensive-stage disease (ED-SCLC), indicating a high unmet need.
Article
Oncology
Jarushka Naidoo, Scott Antonia, Yi-Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann, Michael Newton, Corinne Faivre-Finn
Summary: This study examined the efficacy of immunotherapy in patients with EGFR-mutant NSCLC. The results showed that durvalumab had similar PFS and OS compared to placebo, but due to small sample size and lack of prospective studies, further research is needed to determine the optimal treatment for EGFR-mutant NSCLC.
JOURNAL OF THORACIC ONCOLOGY
(2023)
Letter
Oncology
Alan McWilliam, Azadeh Abravan, Kathryn Banfill, Corinne Faivre-Finn, Marcel van Herk
JOURNAL OF THORACIC ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Alyaa M. Ajabnoor, Rosa Parisi, Salwa S. Zghebi, Darren M. Ashcroft, Corinne Faivre-Finn, Charlotte Morris, Mamas A. Mamas, Evangelos Kontopantelis
Summary: The study examines the association between certain types of cancer and the balance between stroke and bleeding risk in patients with atrial fibrillation.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Meeting Abstract
Health Care Sciences & Services
Cathryn Crockett, Danya Abdulwahid, Neil Bayman, Fiona Blackhall, Raffaele Califano, Clara Chan, Joanna Coote, Laura Cove-Smith, Fabio Gomes, Margaret Harris, Sarah Hughes, Colin Lindsay, Laura Pemberton, Shereen Rafee, Hamid Sheikh, Yvonne Summers, Paul Taylor, David Woolf, Corinne Faivre-Finn
QUALITY OF LIFE RESEARCH
(2023)
Meeting Abstract
Oncology
Colin R. Lindsay, Pantelis Nicola, Andreas Gruber, Kate Brown, Mathew Carter, Helen Adderley, Shereen Rafee, Anna Moss, Andrew Wallace, George Burghel, Helene Schlecht, Katie Baker, Sharzad Moghadam, Jane Rogan, Jamie Weaver, Angeliki Malliri, William Newman, Fiona Blackhall, David Wedge
Meeting Abstract
Oncology
Holly Beckett, Clare Greenbaum, Catherine O'Hara, Lena RIchards, Claire Shanahan, Neil Bayman, Fiona Blackhall, Raffaele Califano, Clara Chan, Joanna Coote, Laura Cove-Smith, Corinne Faivre-Finn, Fabio Gomes, Margaret Harris, Sarah Hughes, Colin Lindsay, Laura Pemberton, Yvonne Summers, Paul Taylor, David Woolf, Hamid Sheikh
Article
Oncology
Ehsan Ghorani, Matteo Quartagno, Fiona Blackhall, Duncan C. Gilbert, Mary O'Brien, Christian Ottensmeier, Elena Pizzo, James Spicer, Alex Williams, Philip Badman, Mahesh K. B. Parmar, Michael J. Seckl
Summary: Some immunotherapy dosing regimens for advanced cancer patients may result in overtreatment, and new approaches are needed to reduce unnecessary treatment. REFINE-Lung is a UK multicentre phase 3 study that uses a novel design to determine the optimal dose frequency of pembrolizumab.
Meeting Abstract
Oncology
Cathryn Crockett, James Price, Mai Pham, Danya Abdulwahid, Neil Bayman, Fiona Blackhall, Layla Bostock, Raffaele Califano, Clara Chan, Joanna Coote, Laura Cove-Smith, Marie Eaton, Jacqueline Fenemore, Fabio Gomes, Margaret Harris, Emma Halkyard, Sarah Hughes, Colin Lindsay, Hilary Neal, Delyth McEntee, Laura Pemberton, Hamid Sheikh, Yvonne Summers, Paul Taylor, David Woolf, Janelle Yorke, Corinne Faivre-Finn
Meeting Abstract
Oncology
Emma Halkyard, Fiona Blackhall, Layla Bostock, Raffaele Califano, Mathew Carter, Marie Eaton, Matt Evison, Jackie Fenemore, Fabio Gomes, Sarah Hughes, Kashif Khan, Colin Lindsay, Delyth McEntee, Laura Moliner, Hilary Neal, Yvonne Summers, Paul Taylor, Laura Cove-Smith
Meeting Abstract
Oncology
Jacob Lewis, Laura Woodhouse, Helen Adderley, Matt Carter, Kate Brown, George Morrissey, Pantelis Nicola, Jamie Weaver, Raffaele Califano, Yvonne Summers, Laura Cove-Smith, Sarah Hughes, Paul Taylor, Fiona Blackhall, Colin Lindsay